Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May 11;2(3):245-247.
doi: 10.1016/j.xkme.2020.05.001. eCollection 2020 May-Jun.

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection

Hitesh H Shah  1 , Nupur N Uppal  1 , Steven Fishbane  1
Affiliations
Editorial

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection

Hitesh H Shah et al. Kidney Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Factors related to anemia that have been related to adverse outcomes. Most of these relationships are demonstrated associations but without proof of causality (represented by dashed lines with arrows). Solid lines are used to display causal relationships, anemia and erythropoiesis-stimulating agent (ESA) hyporesponse, and higher ESA doses.
See this image and copyright information in PMC

Comment on

References

    1. Karaboyas A., Morgenstern H., Fleischer N.L. Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: a self-matched longitudinal study of anemia management in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Kidney Med. 2020;2(3):286–296. - PMC - PubMed
    1. Kainz A., Mayer B., Kramar R., Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant. 2010;25(11):3701–3706. - PMC - PubMed
    1. Zhang Y., Thamer M., Stefanik K., Kaufman J., Cotter D.J. Epoetin requirements predict mortality in the secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Am J Kidney Dis. 2004;44(5):866–876. - PubMed
    1. Szczech L.A., Barnhart H.X., Inrig J.K. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–798. - PMC - PubMed
    1. Solomon S.D., Uno H., Lewis E.F. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. N Engl J Med. 2010;363(12):1146–1155. - PubMed

LinkOut - more resources